Hercules Capital, Inc. (HTGC)
| Market Cap | 3.08B |
| Revenue (ttm) | 494.41M |
| Net Income (ttm) | 318.41M |
| Shares Out | 160.19M |
| EPS (ttm) | 2.01 |
| PE Ratio | 9.55 |
| Forward PE | 9.62 |
| Dividend | $1.60 (8.33%) |
| Ex-Dividend Date | Nov 13, 2024 |
| Volume | 1,061,416 |
| Open | 18.98 |
| Previous Close | 19.02 |
| Day's Range | 18.98 - 19.48 |
| 52-Week Range | 16.32 - 21.78 |
| Beta | 1.32 |
| Analysts | Buy |
| Price Target | 20.31 (+5.73%) |
| Earnings Date | Feb 13, 2025 |
About HTGC
Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management ... [Read more]
Financial Performance
In 2023, Hercules Capital's revenue was $460.67 million, an increase of 43.20% compared to the previous year's $321.69 million. Earnings were $334.14 million, an increase of 234.55%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for HTGC stock is "Buy." The 12-month stock price forecast is $20.31, which is an increase of 5.73% from the latest price.
News
Remodel Health Raises More Than $100 Million to Continue Expansion in ICHRA Market
INDIANAPOLIS , Dec. 19, 2024 /PRNewswire/ -- Remodel Health , the #1 Individual Coverage Health Reimbursement Arrangement (ICHRA) provider for brokers, today announced it has raised more than $100 mil...
Invest In $95,000 BDC Portfolio For $10,000 Annual Income And Durable Compounding
Private credit/BDC investments offer exposure to structural growth and a significant portfolio yield enhancement. Yet, we have to be extra careful of not falling into value traps and investing in unsu...
Hercules Capital: Are The Dividends Safe? I'm Buying!
Hercules Capital offers an attractive income yield (~8.4% regular dividends) and focuses on US businesses in technology, life sciences, SaaS, and renewable technology sectors. Since Hercules Capital o...
Hercules Capital Renews and Increases Its Multi-Currency SMBC Credit Facility to $300.0 Million
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and establishe...
Hercules Capital: This 10% Yield Is Rock Solid
Hercules Capital offers a 10% dividend yield, supported by strong balance sheet quality and low non-accrual percentage of 0.6%. The BDC focuses on venture-backed tech companies, achieving consistent g...
Structuring Portfolio To Achieve Durable 7% Yield With 7% Income Growth
One of the main drawbacks of high durable income investing is the opportunity cost that comes from reduced income growth potential. However, as I have shown in this article, by being very selective, i...
Behavox Secures $70 Million Credit Facility from Hercules Capital for Strategic Expansion
LONDON--(BUSINESS WIRE)--Behavox, a leading provider of AI-driven compliance solutions for Financial Services, announced today that it has secured a $70 million credit facility from Hercules Capital, ...
Hercules Capital, Inc. (HTGC) Q3 2024 Earnings Call Transcript
Hercules Capital, Inc. (NYSE:HTGC) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Michael Hara - Investor Relations and Corporate Communications Scott Bluestein - C...
Hercules Capital Reports Third Quarter 2024 Financial Results
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and establishe...
Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the Third Quarter 2024
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty finance provider to innovative, venture, growth and established...
Path To $10,000 Of Annual Income In 5 Years Through SWAN Dividend Investing
In this article, I explore the potential path on how one could achieve $10,000 of annual portfolio income in just a 5-year period by accumulating a capital base from zero. I provide a sample portfolio...
3 BDCs With Highest Dividend Coverage Levels: Only One Is A Defensive Leader
The investment environment for BDCs remains solid, but there are some clear risks, which call for extra caution. One of the ways to protect current income streams from BDC allocations is to focus on h...
Hercules Capital: The Valuation Is My Only Concern
Hercules Capital, Inc. offers an attractive dividend yield of nearly 10%, supported by strong net investment income coverage. Portfolio quality shows slight deterioration with an increase in Grade 3 r...
Hercules Capital Announces Date for Release of Third Quarter 2024 Financial Results and Conference Call
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and establishe...
Invest In All Weather BDC Dividend Portfolio
The All Weather Portfolio concept introduced by Ray Dalio aims for stable returns through largely uncorrelated investment exposures. In this article, I have tried to apply the essence of such a constr...
Hercules Capital: Trades At Premium To NAV, But Distribution Coverage Is Strong
I maintain a hold rating on Hercules Capital due to its high premium to NAV, awaiting a price drop before accumulating shares. HTGC's portfolio emphasizes senior secured first lien debt, providing hig...
Hercules Capital: How Good Is This 10% Yield?
Hercules Capital offers a ~10% dividend yield and has a strong track record, but currently trades at a significant premium to its net asset value. The company is well-diversified with a focus on Techn...
Dividend Cut Alert For 2 Deeply Undervalued 11%+ Yields
Typically, stocks with at-risk dividends should be avoided. That said, there are exceptions to every rule. I share two high-yielding stocks that look like attractive buys to me even though their divid...
Hercules Capital Receives Reaffirmed Baa3 Investment Grade Rating with Revised Outlook to Positive from Moody's Investors Service
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and establishe...
The Best BDC To Buy For Fed Rate Cuts
The Federal Reserve's 50 basis point rate cut impacts BDCs, which are sensitive to short-term rate changes, affecting their net investment income. BDCs thrive during rate hikes but face challenges wit...
Hercules Capital Announces Upcoming Event for the Financial Community
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and establishe...
Is Hercules Capital Worthy Of Its Name? Volatility Is Coming
Hercules Capital is a top-tier BDC with a strong track record, focusing on first-lien debt investments across five sectors from the 'new economy'. HTGC's floating-rate loans benefit from high-interest...
Hercules Capital: The Yield And Underlying Value Remain Attractive
Hercules Capital is my only VC-focused BDC with a buy rating, mainly due to its disciplined credit underwriting and defensive yield. Since my initial January 2024 thesis, HTGC has delivered significan...
Market Jitters, Dividend Winners: 2 High-Yields To Buy Now
Recent market volatility has created attractive buying opportunities in high-yield stocks like Hercules Capital and Plains All American. HTGC offers a 10.4% total dividend yield, driven by a low-cost ...
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...